Literature DB >> 21757153

Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Byambaa Enkhmaa1, Erdembileg Anuurad, Zeynep Ozturk, Wei Zhang, Thomas A Pearson, Lars Berglund.   

Abstract

Lipoprotein(a) [Lp(a)] is a cardiovascular disease (CVD) risk factor, where inflammation impacts levels differentially across ethnicity. We investigated the effect of systemic [serum amyloid A (SAA)] and vascular [pentraxin-3 (PTX-3)] inflammation on Lp(a) levels across different apolipoprotein(a) [apo(a)] sizes in a biethnic population. Lp(a) and allele-specific apo(a) levels, apo(a) sizes, SAA, and PTX-3 levels were determined in 336 Caucasians and 224 African Americans. We dichotomized subjects into 2 groups using the respective median SAA (29.8 and 41.5 mg/dL for Caucasians and African Americans, respectively) or PTX-3 levels (1.6 and 1.1 ng/mL for Caucasians and African Americans, respectively). Among African Americans, but not in Caucasians, Lp(a) levels were increased (146 vs 117 nmol/L, P = 0.024) in the high versus low SAA group. No difference was observed across PTX-3 groups. Furthermore, among African Americans with smaller (<26 K4 repeats) apo(a) sizes, allele-specific apo(a) levels (111 vs 79 nmol/L, P = 0.020) were increased in the high versus low SAA group. Again, no difference was observed for PTX-3. We did not find any significant associations between allele-specific apo(a) and SAA or PTX-3 levels among Caucasians with smaller (<26 K4) apo(a) sizes. In conclusion, increased levels of SAA, but not PTX-3, were associated significantly with higher Lp(a) levels for smaller (<26 K4) apo(a) sizes in African Americans. Our results implicate that a proinflammatory stimulus may result in an increased cardiovascular risk through a selective increase in Lp(a) levels among African Americans who carry a smaller apo(a) size.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757153      PMCID: PMC3137802          DOI: 10.1016/j.trsl.2011.01.004

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  40 in total

1.  Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids.

Authors:  Peter S Gargalovic; Minori Imura; Bin Zhang; Nima M Gharavi; Michael J Clark; Joanne Pagnon; Wen-Pin Yang; Aiqing He; Amy Truong; Shilpa Patel; Stanley F Nelson; Steve Horvath; Judith A Berliner; Todd G Kirchgessner; Aldons J Lusis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-15       Impact factor: 11.205

2.  ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study.

Authors:  Erdembileg Anuurad; Guijing Lu; Jill Rubin; Thomas A Pearson; Lars Berglund
Journal:  J Lipid Res       Date:  2006-12-15       Impact factor: 5.922

Review 3.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

Review 4.  Serum amyloid A, the major vertebrate acute-phase reactant.

Authors:  C M Uhlar; A S Whitehead
Journal:  Eur J Biochem       Date:  1999-10

Review 5.  Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity.

Authors:  Martine Szyper Kravitz; Milena Pitashny; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

6.  Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a].

Authors:  Jill Rubin; Han Jo Kim; Thomas A Pearson; Steve Holleran; Rajasekhar Ramakrishnan; Lars Berglund
Journal:  J Lipid Res       Date:  2006-02-22       Impact factor: 5.922

7.  Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.

Authors:  As Savchenko; M Imamura; R Ohashi; S Jiang; T Kawasaki; G Hasegawa; I Emura; H Iwanari; M Sagara; T Tanaka; T Hamakubo; T Kodama; M Naito
Journal:  J Pathol       Date:  2008-05       Impact factor: 7.996

Review 8.  New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.

Authors:  Sotirios Tsimikas; Loukas D Tsironis; Alexandros D Tselepis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-12       Impact factor: 8.311

9.  Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.

Authors:  Shahar Lavi; Joseph P McConnell; Charanjit S Rihal; Abhiram Prasad; Verghese Mathew; Lilach O Lerman; Amir Lerman
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

10.  The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.

Authors:  Sébastien Jaillon; Giuseppe Peri; Yves Delneste; Isabelle Frémaux; Andrea Doni; Federica Moalli; Cecilia Garlanda; Luigina Romani; Hugues Gascan; Silvia Bellocchio; Silvia Bozza; Marco A Cassatella; Pascale Jeannin; Alberto Mantovani
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

View more
  9 in total

1.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

2.  Age as a modulator of inflammatory cardiovascular risk factors.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Zeynep Gungor; Wei Zhang; Russell P Tracy; Thomas A Pearson; Kyoungmi Kim; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-23       Impact factor: 8.311

Review 3.  Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Tina Tran; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2011-07-12       Impact factor: 1.894

4.  Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Chin-Shang Li; Robert Kaplan; Jason Lazar; Dan Merenstein; Roksana Karim; Brad Aouizerat; Mardge Cohen; Kenneth Butler; Savita Pahwa; Igho Ofotokun; Adaora A Adimora; Elizabeth Golub; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-23       Impact factor: 8.311

5.  Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Kyoungmi Kim; Lars Berglund
Journal:  J Lipid Res       Date:  2019-07-18       Impact factor: 5.922

6.  Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Kyoungmi Kim; Lars Berglund
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

8.  Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Adnan Abbuthalha; Parneet Kaur; Jasmeen Visla; Sidika Karakas; Lars Berglund
Journal:  Clin Endocrinol (Oxf)       Date:  2015-10-05       Impact factor: 3.478

9.  Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden.

Authors:  Anuurad Erdembileg; Annie Mirsoian; Byambaa Enkhmaa; Wei Zhang; Laurel A Beckett; William J Murphy; Lars F Berglund
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.